Introduction
Zonisamide is a relatively new antiepileptic drug (AED) that has been shown in animal models to have multiple mechanisms of action, which in part explains its efficacy in a broad range of seizure types. 1 These include blocking sustained repetitive action potentials of voltage-gated sodium channels, 2 reducing T-type calcium channel current 3 and modulating neurotransmitter systems such as GABAergic and glutamate systems. 4 It has favourable pharmacokinetic properties 5 and few drug interactions. [6] [7] [8] [9] Zonisamide has benefited from extensive clinical experience. In Japan, it has been approved since 1989 for the adjunctive treatment or monotherapy of partial or generalised seizures in adults and children over 1 year old. 10, 11 Approval in the United
States in 2000 was specifically for adjunctive therapy of partial seizures in adults. The same label was extended to Europe in 2005 after four randomised, placebo-controlled studies showed efficacy in treating refractory partial seizures in adults. [12] [13] [14] [15] There are no published randomised clinical trials (RCT) of zonisamide use in children. There are several open-label adjunctive or 'add-on' studies reporting on children with mostly refractory seizures. 10, 11, [16] [17] [18] [19] [20] [21] The responder rates, defined as a reduction in seizure frequency of at least 50%, range from 15% to 48.7% 10, [16] [17] [18] [19] [20] 19 At first glance, the drug appears to be as effective as other newer AEDs including lamotrigine (45% responder rate) 22 and topiramate (39% responder rate). 22 However, these latter figures are derived from placebo-controlled RCTs and comparisons regarding relative efficacy cannot be made. Several studies have also reported the use of zonisamide in children as monotherapy or polytherapy in specific epilepsy syndromes. Responder rates for zonisamide monotherapy in a Purpose: To evaluate the effectiveness and tolerability of zonisamide in children with epilepsy. Method: Retrospective case note review of young people (less than 19 years) with epilepsy from three UK tertiary centres who received treatment with zonisamide and were followed up for a minimum of 12 months. Results: Fifty-seven children were included, aged 1.5-18.5 (median, 12) years. Thirty-three (57.9%) patients had generalised epilepsy, 21 (36.8%) focal epilepsy, and three (5.3%) a mixed, generalised and focal, epilepsy. Fifty-six of the 57 patients had been refractory to at least three previous antiepileptic drugs. The maintenance dose of zonisamide was [range (median)] 0.7-14 (5) mg/kg/day. The median duration of treatment for all patients was 12 (range 0.25-35) months. After 2 months of treatment, 51 patients remained on zonisamide, 18 (35.3%) of whom demonstrated a 50% reduction in seizure frequency. At the end of the follow-up period, there was a loss of effect for some patients. Thirteen (25.5%) of the 51 patients continued to demonstrate a 50% reduction in seizure frequency whilst two who had become seizure-free started having seizures again. Six (11.8%) had <50% reduction, twenty-four (47%) had no change, and eight (15.7%) had increasing seizures. Twenty-five (43.9%) patients reported unwanted effects although this contributed to the withdrawal of zonisamide in only ten (17.6%) patients. Conclusions: Zonisamide appeared to be a reasonably effective and generally well-tolerated antiepileptic drug in a heterogeneous group of 57 children with poorly controlled epilepsy and provides another treatment option for children with refractory seizures.
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variety of seizure disorders ranged from 75% to 77%. 23, 24 Finally, reports of zonisamide in infantile spasms (20-36% spasmfree), 10, 11, 25 juvenile myoclonic epilepsy (80% responder rate), 26 absence seizures (51.1% seizure-free), 27 and Lennox-Gastaut syndrome (35-51.6% responder rate) 11, 28 demonstrate its efficacy in a wide range of epilepsy types. This retrospective study describes the effectiveness and tolerability of zonisamide in the treatment of children with refractory epilepsy from three paediatric tertiary centres in the UK.
Methods
This was a retrospective study of zonisamide use in children with epilepsy from three paediatric neurology regional centres in the UK: Royal Manchester Children's Hospital, Alder Hey Children's NHS Foundation Trust (Liverpool) and Royal Preston Hospital. Patients who had been given a prescription for zonisamide between September 2004 and January 2008 were identified from hospital and pharmacy records. Medical records were reviewed and clinical information was recorded on a standard proforma. Where possible, seizure types and epilepsy syndromes were classified using clinical, EEG and neuroimaging data. Case notes were reviewed and data was extracted for all patients who had been followed up for a minimum period of 12 months since starting zonisamide. The study was registered with the Trusts' audit departments. All notes were handled in accordance with national guidelines. Ethical approval was not required.
For the purposes of this study, the effectiveness of zonisamide was evaluated by comparing changes in seizure frequency from seizure diaries/data completed by caregivers. The baseline seizure frequency was obtained from the clinic letter written at the time zonisamide was first prescribed. A judgement on the relative change in seizure frequency was inferred from subsequent clinic letters, and was documented as follows: seizure-free, 50% reduction seizure frequency, <50% reduction frequency, no change, or increased seizures. Response rates were assessed at the following times: 2 months after starting zonisamide, at the time a decision was made to withdraw zonisamide and at the last recorded follow-up appointment for those who continued on zonisamide. Initial responders were defined as those patients who achieved a 50% decrease in seizure frequency at 2 months following the introduction of the drug.
Tolerability was assessed by recording any documented unwanted effects. Treatment retention (percentage of patients remaining on zonisamide) is considered a good indicator of effectiveness and tolerability and this was reported 12 months after the commencement of zonisamide.
Data analysis was descriptive. Selected categorical variables were compared using Chi-square analysis and continuous variables using independent t-test.
Results

Patient characteristics
Fifty-seven children were identified and evaluated (32 females and 25 males). The median age at the time of initiation of zonisamide treatment was 12 years (range 1.5-18.5 years). Patients were classified according to seizure type (generalised, focal, mixed), aetiology (idiopathic, cryptogenic or symptomatic), and epilepsy syndrome. Fifty-six of the 57 patients had failed to achieve acceptable seizure control on a minimum of three previous AEDs (median 8: range 2-16). Four patients had undergone epilepsy surgery (corpus callostomy in two, and one each, parietal and temporal lobectomies and hemispherectomy). Eight had undergone insertion of a vagal nerve stimulator (VNS) prior to treatment with zonisamide and stimulation was continued in all eight patients throughout the study. Most patients had moderate to severe learning difficulties. A summary of patients' characteristics and a breakdown of seizure types and aetiology are presented in Table 1 .
Zonisamide treatment and concomitant antiepileptic drugs
Zonisamide was initiated as adjunctive therapy in all 57 patients. During the course of treatment, three patients had their concomitant AEDs withdrawn and received zonisamide as monotherapy. The median (range) duration of zonisamide treatment was 12 (0.25-35) months. The median (range) final maintenance dose was 5 (0.7-14) mg/kg/day. The median (range) number of concomitant AEDs used was 2 (1-4) with the most commonly used ones being lamotrigine, levetiracetam, sodium valproate, and topiramate (Table 2) . Patients on VNS therapy did not have many adjustments to the VNS settings during the study. 
Effectiveness
Six patients stopped taking zonisamide before 2 months: in two no reason was documented, in two there were intolerable unwanted effects (allergic rash in one, and a combination of tiredness, anorexia and emotional lability in one) and in the remaining two, the seizure frequency had increased. We excluded these six patients from analysis, as their period on treatment was considered insufficient to adequately assess the drug's effectiveness.
Of the remaining 51 children, 18 (35.3%) were designated as 'initial responders' 2 months after treatment was commenced. This effectiveness was subsequently lost in five of these 18 patients between 4 and 8 months of treatment. During this time, one or more of the concomitant AEDs had been withdrawn in three of five children. Seizures deteriorated in one patient following a reduction in the dose of zonisamide because of side-effects.
The median (range) length of follow-up for the 51 patients who remained on zonisamide was 12 (2-35) months. Thirteen (25.5%) of the 51 patients continued to demonstrate a reduction in seizure frequency of 50%. Six (11.8%) patients were classified as having a <50% reduction in seizure frequency or some improvement in their epilepsy. Twenty-four (47%) patients showed no change in their seizure frequency, and eight (15.7%) had increased seizures.
Two children became seizure-free during treatment with zonisamide but the effects of the drug diminished with time. One with symptomatic focal epilepsy, secondary to focal (frontal) cortical dysplasia, became seizure-free for 18 months but then experienced a recurrence of infrequent focal sensory auras which did not progress. One patient with Lennox-Gastaut syndrome, with a pre-treatment daily seizure frequency of 150 brief tonic seizures was initially seizure-free for the first 5 months but then developed breakthrough tonic seizures, coinciding with the withdrawal of a concomitant AED. Both patients continued with zonisamide treatment as it still produced a >50% reduction in their seizure frequency.
Analysis of effectiveness by seizure type and aetiology was undertaken in 51 patients ( Figs. 1 and 2) . Four (23.5%) of 17 patients with focal, eight (25%) of 32 patients with generalised, and one (50%) of two patients with 'mixed' epilepsy demonstrated a 50% reduction in seizure frequency. The difference was not statistically significant (p > 0.5). Four (18%) of 22 patients with symptomatic and nine (31%) of 29 with cryptogenic epilepsy showed a 50% reduction in seizure frequency. This did not reach statistical significance (p > 0.5). Nine children had drug-resistant infantile or epileptic spasms in isolation or in combination with other seizure types. Three (33.3%) of these nine demonstrated a reduction in spasms of 50%. Eight had Lennox-Gastaut syndrome but only one (12.5%) patient had a 50% reduction in seizure frequency.
Three patients had gradual withdrawal of all their concomitant AEDs and subsequently received zonisamide as monotherapy. One with symptomatic focal epilepsy discontinued zonisamide after 3 months as there was no improvement in seizure control and was then treated with sodium valproate. The remaining two children with cryptogenic generalised and cryptogenic focal epilepsy had a reduction in seizure frequency of 50% at doses of 7.5 and 8.8 mg/ kg/day. They continued with zonisamide as monotherapy although one of these children had worsening behaviour which may or may not have been treatment-related.
Retention and tolerability
Thirty-one (54.4%) of the 57 patients remained on zonisamide treatment 1 year after it was started. At the end of the study period, 30 (52.7%) had discontinued treatment: 13 (22.8%) because of lack of therapeutic benefit, five (8.8%) because of unwanted effects, five (8.8%) because of an increase in seizure frequency, five (8.8%) because of a combination of increase in seizure frequency and unwanted effects, and two (3.5%) following parents' requests (no reason documented). Two patients died from respiratory complications, one with Ohtahara syndrome and one with cryptogenic infantile epileptic encephalopathy; they had received zonisamide for 26 and 24 months, respectively.
Twenty-five (43.9%) of the 57 patients reported at least one unwanted effect after commencing zonisamide ( Table 3 ). The most frequently reported were anorexia (12.3%), fatigue (12.3%), agitation or irritability (10.5%), and somnolence (8.8%). Most patients had mild to moderate unwanted effects which resolved spontaneously or after an adjustment of the dose of zonisamide.
Of the ten children who stopped zonisamide because of unwanted effects, two developed psychotic symptoms manifest by aggressiveness and visual hallucinations 2.5 and 12 months after starting treatment. The doses of zonisamide for these children were 4 and 2.8 mg/kg/day, respectively. One of these patients had experienced similar episodes prior to the use of zonisamide. Symptoms resolved in both patients after withdrawal of the drug. In the remaining eight patients, the unwanted effects that contributed to the decision to withdraw zonisamide included: fatigue, anorexia, weight loss, abdominal pain (1); diarrhoea and somnolence (1); hypersensitivity syndrome with elevated liver function tests (1); fatigue, anorexia and emotional lability (1); anorexia and somnolence (1); drowsiness (1); lethargy (1); irritability (1).
Discussion
Zonisamide has been prescribed in Japan for the last 20 years but has only received a license for the adjunctive treatment of partial seizures in adults in the UK in 2005. In addition, there are few controlled trials of zonisamide in treating the paediatric epilepsies. Consequently, most paediatric neurologists use new AEDs off-license in children who have chronic and previously drugresistant epilepsy. This report describes the use of zonisamide in a heterogenous group of children with refractory epilepsy and as such, it represents one of the largest reported experiences of this anticonvulsant.
We have found that zonisamide is reasonably effective: 35.3% of our patients were initial responders and 25.5% continued to demonstrate this response at the time of last follow-up. Analysis by seizure type showed that 23.5% with focal and 25% with generalised seizures were classified as responders. Seizures were reported to have increased in frequency in ten (17.6%) children, with most (eight) occurring during the first 3 months of treatment with zonisamide. There was no obvious correlation between response and either the aetiology of the epilepsy or seizure types. Unwanted side-effects were common, occurring in almost half of the children. However, these led to the discontinuation of treatment in only ten (17.6%) children.
Initial data on the use of zonisamide in children originated from Japan and has been summarised by Glauser and Pellock, and Ohtahara. 10, 11 Four open-label trials assessed zonisamide as adjunctive therapy in children with previously drug-resistant epilepsy. The pooled results from these trials showed the responder rate to be 34% (47/137) of those with partial-onset seizures and only 15% (8/54) of those with generalised-onset seizures. 10, 11 Five openlabel trials assessed zonisamide as monotherapy in the treatment of newly diagnosed and treatment-resistant epilepsy with a responder rate of between 71 and 78%. 10, 11 One large, open-label, phase III trial of 393 patients represents the only well-controlled trial of zonisamide use in children to date and this demonstrated an overall responder rate of 44.3%. 29 Kim et al. 17 recently evaluated zonisamide as monotherapy and adjunctive therapy in 68 children with predominantly refractory epilepsy. Five were already in remission prior to commencing zonisamide. They reported a responder rate of 46.8%. Another study showed a responder rate of 42% 12 months after treatment in 35 children with intractable epilepsy. 18 Kluger et al. 19 reported a 41.7% responder rate at the end of an 18-month follow-up on 24
patients with highly refractory childhood-onset epilepsy followed for at least 18 months. Finally, Coppola et al. observed a responder rate in 48.7% of 82 children and young adults (aged 3-34 years) with refractory epilepsy. 20 Our study shows a lower responder rate than most of these earlier studies. The reasons for this are likely to be multiple. These include the fact that our study involved a high proportion of children with generalised epilepsy (57.9%), compared to previous studies where the proportion ranged from 12.5% to 43%. [18] [19] [20] Earlier studies had indicated a lower response rate in patients with a generalised epilepsy. 10, 11 Seven of our 33 with generalised epilepsy had Lennox-Gastaut syndrome. Although pooled analysis in Japan 11 and a recent study in Korea 28 found a responder rate of 35% and 51.6%, respectively, this remains an extremely difficult epilepsy syndrome to treat. An additional explanation is that the majority of patients in the current study were children with highly intractable epilepsy, as manifest by the median number of previous (and ineffective) antiepileptic drugs and the number of patients who had VNS. Zonisamide was one of few treatment options left to consider in this highly refractory population.
There was a loss of effectiveness during the course of treatment with zonisamide in five of the 18 initial responders, as well as both the patients who had been seizure-free. Withdrawal of concomitant AEDs and reduction of dose of zonisamide were factors in five of these seven patients that may have contributed to the loss of effect. There has been increasing evidence about the development of tolerance to effect of most AEDs during prolonged treatment and, although an infrequent cause, would be plausible especially in such a refractory population. 30 The doses of zonisamide used in the current study (0.7-14 mg/ kg/day) were comparable to those used in other studies with the lower maintenance doses quoted as being between 0.7 and 4 mg/ kg/day and the higher doses between 8 and up to 35 mg/kg/ day. 10, [16] [17] [18] [19] [20] [21] The median dose of zonisamide in our responders was higher (6.2 mg/kg/day) when compared to the rest of the group (4.5 mg/kg/day), but this difference was not statistically significant (p > 0.05). Other studies 18, 23 have found the converse to be true, i.e. the dose in responders was lower than in non-responders, suggesting that further increases in dose may not be justified if no response is seen at moderate doses. In addition, the median dose of zonisamide in the 25 children who reported unwanted effects was lower (4.4 mg/kg/day), when compared to those who did not report any side-effects (6.35 mg/kg/day). This has been reported previously and it was suggested that it was due to different rates of clearance or an idiosyncratic response to the medication. 18 The incidence of unwanted effects (43.9%) was lower than in other published series (46-71.4%). [16] [17] [18] [19] 21 One reason for this may the high proportion of children with severe learning difficulties who may not have been able to describe unwanted effects. It has been reported that behavioural and psychiatric effects with the group of AEDs classified as modulators of voltage-gated cationic channels (which includes zonisamide) are infrequent in comparison with other groups of antiepileptics. 31 However, a high incidence of psychotic symptoms with zonisamide use was noted in two Japanese studies, one involving children (6%) and reported in the paper by Glauser and Pellock 10 and the other involving adult and paediatric patients (18.9%). 32 Kanner 33 summarised findings from several studies suggesting that psychiatric events during treatment with a number of AEDs occur more frequently in patients at risk of psychiatric disorders. In our study, the two children with psychosis had susceptible neuropsychiatric profiles; one had a diagnosis of Landau-Kleffner syndrome and the other had an unidentified encephalopathy with previous episodes of agitation and confusion. It is unclear whether the recurrence of these psychological symptoms was directly related to the use of zonisamide. Table 3 Unwanted effects (n = 57).
Unwanted effects n (%) Although this study is retrospective and subjective, it does contribute to the existing knowledge and experience of the effectiveness and safety of zonisamide in children. It provides data that suggests that treatment with zonisamide may produce sustained improvement in seizure control in some children with previously drug-resistant epilepsy. There was no obvious correlation between effectiveness and seizure type or aetiology. Zonisamide does appear to offer an additional treatment option for children with refractory epilepsy. However, it remains unclear as to whether it is as effective as other AEDs including sodium valproate, topiramate or lamotrigine. This can only be answered by undertaking randomised controlled trials which compare zonisamide with these other anticonvulsants.
